NuCana plc (NCNA) Stock Score, Valuation & Financial Research

NuCana plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NCNA

NuCana plc does not currently have a complete Wall Street Score. The stored market price is USD 1.12. These figures are a research snapshot, not a buy or sell recommendation.

What NuCana plc does

NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

NuCana is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of cancer therapies using its proprietary ProTide technology to improve the efficacy and safety of existing chemotherapy agents.

Products and services

  • The company is developing a pipeline of ProTide-based product candidates, including NUC-3373, NUC-7738, and NUC-7804, which are designed to overcome resistance mechanisms associated with traditional nucleoside analog chemotherapies.

Customer types

Oncology patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on various third-party CROs and CMOs for clinical trial management, drug substance manufacturing, and supply chain services. Specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Established pharmaceutical and biotechnology companies — Companies developing oncology therapies, including those focused on nucleoside analogs and other chemotherapy agents. Source

Business strengths to evaluate

  • Proprietary ProTide technology platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of clinical-stage product candidates Source
  • Need for additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NCNA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.12
Market capitalization:
6.79M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -12.86M
Free cash flow:
USD -10.12M
Cash:
USD 25.62M
Total debt:
USD 882.88K
EPS:
USD -2.12

What stands out

  • Free cash flow is USD -10.12M, negative for the stored period.
  • The balance sheet shows USD 25.62M of cash versus USD 882.88K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 24.74M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NCNA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NCNA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NCNA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NCNA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NCNA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research NCNA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.